ArticleAMB Express2020
Synergistic interaction of eugenol and antimicrobial drugs in eradication of single and mixed biofilms of Candida albicans and Streptococcus mutans.
Article in AMB Express, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 59 citations in OpenAlex.
- Chitosan-Coated Mesoporous Silica Nanoparticles Co-Loaded with Curcumin and Amphotericin B: A Drug Delivery Approach for Photodynamic Inhibition of Dual-Species Biofilms.Pharmaceutics · 2026Article
- Synergistic Antifungal Efficacy of Eugenol-Loaded Nanocapsules Combined With Itraconazole Against Trichophyton mentagrophytes.Veterinary medicine and science · 2025Article
- Article
- Natural compounds: new therapeutic approach for inhibition ofFrontiers in pharmacology · 2025Review
- Concomitant Inhibition and Collaring of Dual-Species Biofilms Formed byPharmaceutics · 2024Article
- A Comparative Review of Eugenol and Citral Anticandidal Mechanisms: Partners in Crimes Against Fungi.Molecules (Basel, Switzerland) · 2024Review
- Potential Involvement of Reactive Oxygen Species in the Bactericidal Activity of Eugenol againstPathogens (Basel, Switzerland) · 2024Article
- "Stop, Little Pot" as the Motto of Suppressive Management of Various Microbial Consortia.Microorganisms · 2024Review
- Characterization of Lemongrass Extract (Cymbopagon citratus) Nanoemulsion and Its Application as an Antibiofilm Agent in Acrylic Resin.Journal of pharmacy & bioallied sciences · 2024Article
- Essential Oil Compounds in Combination with Conventional Antibiotics for Dermatology.Molecules (Basel, Switzerland) · 2024Article
- Covalent Conjugates of Allylbenzenes and Terpenoids as Antibiotics Enhancers with the Function of Prolonged Action.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Achievement of the Selectivity of Cytotoxic Agents against Cancer Cells by Creation of Combined Formulation with Terpenoid Adjuvants as Prospects to Overcome Multidrug Resistance.International journal of molecular sciences · 2023Article
- Article
- Clove Essential Oil and Its Main Constituent, Eugenol, as Potential Natural Antifungals againstMolecules (Basel, Switzerland) · 2022Article
- Mannosylated Systems for Targeted Delivery of Antibacterial Drugs to Activated Macrophages.International journal of molecular sciences · 2022Article
- MAPLE Processed Nanostructures for Antimicrobial Coatings.International journal of molecular sciences · 2022Article
- Article
- Cinnamon Leaf and Clove Essential Oils Are Potent Inhibitors ofMicroorganisms · 2022Article
- Mannosylated Polymeric Ligands for Targeted Delivery of Antibacterials and Their Adjuvants to Macrophages for the Enhancement of the Drug Efficiency.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Plant Alkylbenzenes and Terpenoids in the Form of Cyclodextrin Inclusion Complexes as Antibacterial Agents and Levofloxacin Synergists.Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In vitro eradication of the C. albicans and S. mutans mixed biofilms by eugenol alone and in combination with the antimicrobial drugs. Previously characterized strains of C. albicans (CAJ-01 and CAJ-12) and S. mutans MTCC497 were used to evaluate the eradication of biofilms using XTT reduction assay, viability assay, time dependent killing assay and scanning electron microscopy (SEM). Synergistic interaction was assessed by checkerboard method. Sessile MIC (SMIC) of eugenol was equivalent to the planktonic MIC (PMIC) against C. albicans and S. mutans mixed biofilms. SMIC of fluconazole and azithromycin was increased upto 1000-folds over PMIC. Eradication of single or mixed biofilms was evident from the viability assay and SEM. At 1 × MIC of eugenol, log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.